CTOs on the Move


 
Lygos employs cutting edge synthetic biology techniques to generate microbial catalysts to convert agricultural feedstocks into fine and commodity chemicals. Our robust high throughput screening and strain construction facilitates the rapid optimization of pathways to convert cheap and renewable feedstock to high value chemicals.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.lygos.com
  • 1249 Eighth Street
    Berkeley, CA USA 94710
  • Phone: 510.356.0555

Executives

Name Title Contact Details
Nicholas Ohler
Chief Technology Officer Profile

Funding

Lygos raised $15.5M on 07/17/2018

Similar Companies

Curie Co

Curie Co is replacing chemicals with clean, sustainable proteins and enzymes.

Ethicon Endo-Surgery

Ethicon Endo-Surgery is a Cincinnati, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Quincy Bioscience

Quincy Bioscience is a Madison, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Travere Therapeutics

At Travere Therapeutics, our mission is to identify, develop and deliver life-changing therapies to people living with rare disease. #InRareForLife

AsclepiX Therapeutics

AsclepiX Therapeutics is revolutionizing the treatment of retinal diseases and cancer with a singular focus on the design, development, and delivery of novel peptides with the power to inhibit proven key disease pathways.